Krystal Biotech, Inc. P/E Ratio 2016–2025
Krystal Biotech, Inc. reported 36.04 of price-to-earnings ratio for fiscal 2025. That was 31.0% lower than fiscal 2024. Compared with fiscal 2023, the change was -88.7%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 36.04 | -31.0% |
| FY 2024 | 52.22 | -83.6% |
| FY 2023 | 318.10 | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
Source: Krystal Biotech, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open KRYS 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Krystal Biotech, Inc. reported 36.04 of price-to-earnings ratio for fiscal 2025. That was 31.0% lower than fiscal 2024. Compared with fiscal 2023, the change was -88.7%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Krystal Biotech, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeKrystal Biotech, Inc. — frequently asked questions
What is Krystal Biotech, Inc.'s price-to-earnings ratio?
Krystal Biotech, Inc. (KRYS) reported price-to-earnings ratio of 36.04 for fiscal year 2025, per its SEC filings.
How has Krystal Biotech, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2016 and 2025, KRYS's price-to-earnings ratio declined at roughly 21.5% per year (compound annual rate), from 318.10 to 36.04.
Where does this data come from?
Figures are computed from Krystal Biotech, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More KRYS financial history
Full KRYS fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →